Comparison between Elite Pharmaceuticals and Auris Medical

Elite Pharmaceuticals and Auris Medical are both small-capital medical firms, however, one does get curious to know which one is the superior stock? We will be doing a comparison of the two firms on the basis of the risk, the strength of their analyst recommendations, valuation, institutional ownership, profitability, dividends, as well as, earnings.
At present, Auris Medical has a consensus price target of 75.00 dollars, which indicates a likely upside of 2637.23 percent. Considering the potential upside of Auris Medical, research analysts have a clear belief that Auris Medical is more promising than Elite Pharmaceuticals.
The beta of Auris Medical is of negative 0.49, which suggests that the price of its stock 149 percent less volatile than the S&P 500. On the other hand, the beta of Elite Pharmaceuticals is of 0.58, which suggests that the price of its stock is 42 less volatile than the S&P 500.
Coming on to the institutional ownership of Auris Medical, 10.3 percent of its shares are owned by institutional investors. On the other hand, 0.0 percent of Elite Pharmaceuticals shares are owned by institutional investors. Firm insiders own 34.7 percent of Elite Pharmaceuticals shares. Strong institutional ownership acts as an indicating factor that large hedge funds, money managers, as well as, endowments believe a stock is promising and will be having long-term growth.
Elite Pharmaceuticals has an edge over Auris Medical when it comes to earnings and valuation because it has higher revenue and earnings than Auris Medical.
Elite Pharmaceuticals, Inc., a specialty pharma firm, engages in the R & D, manufacture, as well as, licensing of proprietary orally administered controlled-release drug delivery systems and products.
Auris Medical AG is a clinical-stage biopharma firm which has a focus on the development of innovative products to treat inner ear disorders.

,